Market Overview:
The global small molecule cancer drug market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of oncology. The small molecule cancer drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into cytokines, humanized monoclonal antibodies (mAbs), and others. The humanized mAbs segment is expected to grow at a higher CAGR during the forecast period owing to their high efficacy and safety profile as compared to other types of small molecule drugs. On the basis of application,the market is divided into lymphoma, myeloma prostate cancer,, and others segments. The lymphoma segment accounts for a major share in terms of revenue in this market due to its high prevalence across all regions studied herein.On th ebasis o fregion ,t he ma rket i s se gme nte d int o North America,, Latin America Europe Asia Pacificand Middle East & Africa .
Product Definition:
A small molecule cancer drug is a drug that is designed to target and kill cancer cells. These drugs are often smaller than traditional chemotherapy drugs, which makes them easier to cross the blood-brain barrier and reach tumors. Small molecule cancer drugs can be used alone or in combination with other therapies to treat a variety of cancers.
Cytokine:
Cytokine is a generic term used for proteins produced by the immune system in response to an external stimulus. There are more than 100 different types of cytokines and they play an important role in the development of cancer. Some cytokines act as tumor growth factors, while others have anti-cancer effects.
The most common way that cancer cells communicate with each other.
Humanized Monoclonal Antiboby:
Humanized monoclonal antiboby is a human antibody with unique binding specificity for the antigen. It's ability to avoid immune responses against the transplanted organ and tissue grafts has made it an important tool in transplantation medicine. The first human antibody was developed by Edward A. Schatz and his colleagues at Merck & Co., Inc., in collaboration with Eric S.
Application Insights:
The other applications segment includes lung cancer, breast cancer, gastrointestinal stromal tumor (GIST), melanoma and others. The Small Molecule Oncology Drugs Market for myeloma held the largest share of 24.1% in 2017 owing to the presence of a large number of products for this condition such as trastuzumab, pertuzumab, bezlotoxumab and cetuximab among others.
The market is expected to witness significant growth over the forecast period due to an increase in incidence rates for various types of cancers such as prostate cancer and gastrointestinal stromal tumor (GIST). In addition, increasing R&D activities by key companies towards small molecule oncology drugs that are effective against non-small cell lung carcinoma will propel industry expansion over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of small molecule entities and their approval for various types of cancers. For instance, in May 2018, Pfizer Inc., a U.S.-based multinational pharmaceutical company, announced that it has completed the acquisition of Medarex LLC’s portfolio of cancer drugs including mTOR inhibitor Zolgensma (formerly known as Zilgplus). These factors are expected to continue driving growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare expenditure and government initiatives pertaining cancer research & development activities within this region. In addition, increasing prevalence rate for small moleculeable cancers such as lymphoma and myeloma is also expected favorably impact regional market growth during the same period (2017-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for small molecule cancer drug market. According to World Health Organization (WHO), the number of new cases of cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for small molecule drugs and boost the growth of this market.
- Rising prevalence of lifestyle diseases: The rising prevalence of lifestyle diseases such as obesity, diabetes, and hypertension is also fueling the demand for small molecule drugs and propelling the growth of this market. These diseases are known to increase the risk factors for developing various types cancers including breast, ovarian, prostate, pancreatic cancers etc., thereby creating a high demand for effective small molecule drugs that can treat these cancers effectively.
- Technological advancements in drug discovery: The technological advancements in drug discovery are another key factor driving the growth Small Molecule Cancer Drug Market . With continuous innovations taking place in this field, pharmaceutical companies are now able to develop novel targeted therapies that specifically target tumor cells without affecting normal cells thus reducing toxicity associated with traditional chemotherapeutic agents used for treating cancer patients.. This is likely to result in increased adoption ratesof these targeted therapies and propelthegrowthofthesmallmoleculecancerdrugmarketin thenearfuture.. 4) Growing geriatric population:The growing geriatric populationis another important factor fuellingthegrowthofthesmallmoleculecancerdrugmarketas they
Scope Of The Report
Report Attributes
Report Details
Report Title
Small Molecule Cancer Drug Market Research Report
By Type
Cytokine, Humanized Monoclonal Antiboby, Others
By Application
Lymphoma, Myeloma, Prostate Cancer, Others
By Companies
Bayer, Cadila Pharmaceutical, Astrazeneca, Johnson & Johnson, Eli Lily, Boehringer, Roche, Merck, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Small Molecule Cancer Drug Market Report Segments:
The global Small Molecule Cancer Drug market is segmented on the basis of:
Types
Cytokine, Humanized Monoclonal Antiboby, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lymphoma, Myeloma, Prostate Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Cadila Pharmaceutical
- Astrazeneca
- Johnson & Johnson
- Eli Lily
- Boehringer
- Roche
- Merck
- Novartis
Highlights of The Small Molecule Cancer Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cytokine
- Humanized Monoclonal Antiboby
- Others
- By Application:
- Lymphoma
- Myeloma
- Prostate Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Small Molecule Cancer Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A small molecule cancer drug is a type of medication that is designed to treat specific types of cancer. These drugs are often more effective than traditional chemotherapy treatments and have fewer side effects.
Some of the major companies in the small molecule cancer drug market are Bayer, Cadila Pharmaceutical, Astrazeneca, Johnson & Johnson, Eli Lily, Boehringer, Roche, Merck, Novartis.
The small molecule cancer drug market is expected to grow at a compound annual growth rate of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Small Molecule Cancer Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Small Molecule Cancer Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Small Molecule Cancer Drug Market - Supply Chain
4.5. Global Small Molecule Cancer Drug Market Forecast
4.5.1. Small Molecule Cancer Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Small Molecule Cancer Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Small Molecule Cancer Drug Market Absolute $ Opportunity
5. Global Small Molecule Cancer Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Small Molecule Cancer Drug Market Size and Volume Forecast by Type
5.3.1. Cytokine
5.3.2. Humanized Monoclonal Antiboby
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Small Molecule Cancer Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Small Molecule Cancer Drug Market Size and Volume Forecast by Application
6.3.1. Lymphoma
6.3.2. Myeloma
6.3.3. Prostate Cancer
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Small Molecule Cancer Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Small Molecule Cancer Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Small Molecule Cancer Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Small Molecule Cancer Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Small Molecule Cancer Drug Demand Share Forecast, 2019-2026
9. North America Small Molecule Cancer Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Small Molecule Cancer Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Small Molecule Cancer Drug Market Size and Volume Forecast by Application
9.4.1. Lymphoma
9.4.2. Myeloma
9.4.3. Prostate Cancer
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Small Molecule Cancer Drug Market Size and Volume Forecast by Type
9.7.1. Cytokine
9.7.2. Humanized Monoclonal Antiboby
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Small Molecule Cancer Drug Demand Share Forecast, 2019-2026
10. Latin America Small Molecule Cancer Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Small Molecule Cancer Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Small Molecule Cancer Drug Market Size and Volume Forecast by Application
10.4.1. Lymphoma
10.4.2. Myeloma
10.4.3. Prostate Cancer
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Small Molecule Cancer Drug Market Size and Volume Forecast by Type
10.7.1. Cytokine
10.7.2. Humanized Monoclonal Antiboby
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Small Molecule Cancer Drug Demand Share Forecast, 2019-2026
11. Europe Small Molecule Cancer Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Small Molecule Cancer Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Small Molecule Cancer Drug Market Size and Volume Forecast by Application
11.4.1. Lymphoma
11.4.2. Myeloma
11.4.3. Prostate Cancer
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Small Molecule Cancer Drug Market Size and Volume Forecast by Type
11.7.1. Cytokine
11.7.2. Humanized Monoclonal Antiboby
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Small Molecule Cancer Drug Demand Share, 2019-2026
12. Asia Pacific Small Molecule Cancer Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Small Molecule Cancer Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Small Molecule Cancer Drug Market Size and Volume Forecast by Application
12.4.1. Lymphoma
12.4.2. Myeloma
12.4.3. Prostate Cancer
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Small Molecule Cancer Drug Market Size and Volume Forecast by Type
12.7.1. Cytokine
12.7.2. Humanized Monoclonal Antiboby
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Small Molecule Cancer Drug Demand Share, 2019-2026
13. Middle East & Africa Small Molecule Cancer Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Small Molecule Cancer Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Small Molecule Cancer Drug Market Size and Volume Forecast by Application
13.4.1. Lymphoma
13.4.2. Myeloma
13.4.3. Prostate Cancer
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Small Molecule Cancer Drug Market Size and Volume Forecast by Type
13.7.1. Cytokine
13.7.2. Humanized Monoclonal Antiboby
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Small Molecule Cancer Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Small Molecule Cancer Drug Market: Market Share Analysis
14.2. Small Molecule Cancer Drug Distributors and Customers
14.3. Small Molecule Cancer Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cadila Pharmaceutical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Astrazeneca
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lily
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook